gsk

ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with ...

CROWN is the first large, phase IIIb international trial to evaluate the investigational use of long-acting Cabenuva versus daily oral therapy in people with a history of antiretroviral treatment and ...
gsk

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

GSK plc (LSE/NYSE: GSK) today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held ...
gsk

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan

GSK plc (LSE/NYSE: GSK) today announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for ...